Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | BCL9 | O00512 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017678 | 0.99 | HTR2A (0.50) | HTR2ACYP1A2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL29550444 | 0.96 | HTR2A (0.50) | HTR2ACYP1A2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL6816689 | 0.93 | SIGMAR1 (0.52) | HTR2ACYP1A2CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL25184955 | 0.87 | HTR2A (0.47) | HTR2ACYP1A2CYP2D6KMT2ASIGMAR1 | |
| SCHEMBL6820153 | 0.87 | MAPT (0.49) | HTR2ACYP1A2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL313620 | 0.85 | SIGMAR1 (0.51) | HTR2ACYP1A2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL20729823 | 0.84 | HTR2A (0.47) | HTR2ACYP1A2CYP2D6ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL16694512 | 0.84 | SIGMAR1 (0.50) | HTR2ACYP1A2CYP2D6ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL16694856 | 0.83 | ALDH1A1 (0.47) | HTR2ACYP1A2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL21097203 | 0.83 | HTR2A (0.51) | HTR2ACYP1A2CYP2D6ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20050026994-A1 | Use of 2, 4diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | FRANCE DENNIS (US) | 2005-02-03 | — | — | US | disclosed |
| EP-1173413-B1 | USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS | NOVARTIS AG (CH) | 2004-06-30 | — | — | EP | disclosed |
| EP-1173413-A1 | USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS | Novartis AG (CH) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064863-A1 | USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS | NOVARTIS AG (CH) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026994-A1 | Use of 2, 4diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | PSMB3, PSMB2, PSMB1 | HTR2A 972/4885CYP1A2 2124/4885CYP2D6 1129/4885 |
| US-20110059969-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | GPR119, FABP4, ADIPOR2 | HTR2A 203/4885CYP1A2 1352/4885CYP2D6 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.